SAN DIEGO, Jun 18, 2007 (BUSINESS WIRE) -- Concurrent with the annual European Human Genetics Conference inNice, France, Illumina, Inc. (NASDAQ:ILMN) announced today thatIntegraGen SA, a personalized healthcare company focused on thedevelopment and commercialization of molecular diagnostic tests forcomplex diseases and provider of genetic services, has receivedIllumina Certified Service Provider (CSPro(TM)) certification forGoldenGate(R) and Infinium(R) genotyping technologies.
Illumina, a San Diego-based company, is a leading developer,manufacturer, and marketer of next-generation life science tools andintegrated systems for the analysis of genetic variation andbiological function. The GoldenGate assay is Illumina's firstarray-based platform that combines high-sample throughput, highmultiplexing, and single-site CpG resolution for DNA methylationprofiling. The Infinium Whole-Genome Genotyping BeadArray(TM) solutionoffers single or multi-sample BeadChip formats and high-densityarchitecture with the flexibility to add additional custom SNP Assays.
"IntegraGen is a company dedicated to offering high-qualityservices to other research institutes, either private or academic, andis the first laboratory in France to achieve CSPro certification forGoldenGate and Infinium Genotyping," said Karen Possemato, Illumina'sDirector of Corporate Marketing. "By becoming a member of CSPro, theyhave further demonstrated their commitment to the life sciencecommunity, providing delivery of the highest-quality data availablefor genetic analysis applications."
Emmanuel Martin, IntegraGen's Director of Services and Arrays,said: "IntegraGen is proud of its ability to leverage corecompetencies and provide genetic services to the research community.Receiving Illumina CSPro certification is an endorsement of bothIllumina and IntegraGen's commitment to quality, and provides ourcustomers with even greater confidence in our ability meet theirneeds."
As a customer of IntegraGen, Jessica Zucman-Rossi, M.D., Ph.D.,has been using Illumina technology in a pilot study for loss ofheterozygosity (LOH) analysis in liver tumors at the HumanPolymorphism Study Center (CEPH) in Paris. "We also chose Illuminatechnology to test for promoter methylation in liver tumors becausethere were a large number of genes available for testing with thissystem, and the ability to quantify methylation levels is a realadvantage. My team was able to analyze a large number of samples ineach experiment, and the time taken to generate results was short,generating a large amount of data." She added, "The results weattained were excellent, achieving methylation profiling of 96 tumorsamples on more than 1,500 CpG. The data are robust, and we arecurrently preparing a second series of samples."
About Illumina CSPro
Illumina CSPro is a collaborative service provider partnershipdedicated to ensuring the delivery of the highest-quality dataavailable for genetic analysis applications. Illumina CSPros undergo arigorous two-phase certification process that includes minimum datageneration, data certification and on-site audit of the facility andprocesses. For more information about the CSPro program, please visit ww.illumina.com/cspro.
About IntegraGen
IntegraGen is a pioneer in the field of predictive healthcare. Thecompany uses its unique genomic analysis expertise to identify genesassociated with complex diseases and commercializes moleculardiagnostic tests to enable individualized diagnosis, prevention andtreatment.
IntegraGen's proprietary gene mapping technology GenomeHIPprovides fast, reliable, and cost-effective discovery of genetic loci.Paired with strong biostatistics, bioinformatics and fine mappinggenotyping capabilities, IntegraGen has successfully identified andpatented genes associated with early and late onset diseases. Effortsare currently focused on Type-2 Diabetes, Obesity, Autism and Bi-PolarDisorder. Clinical trials for the company's first genetic test forautism, based on internally identified genes, were carried out in Q12007.
Founded in July 2000, IntegraGen has 34 employees and is based inthe French Genopole of Evry, near Paris, France, in Bonn, Germany andin New York, USA. More information can be found at www.integragen.com.
About Illumina
Illumina is a leading developer, manufacturer and marketer ofnext-generation life science tools and integrated systems for thelarge scale analysis of genetic variation and biological function.Using our proprietary technologies, we provide a comprehensive line ofproducts and services that currently serve the sequencing, genotyping,and gene expression markets, and we expect to enter the market formolecular diagnostics. Our customers include leading genomic researchcenters, pharmaceutical companies, academic institutions, clinicalresearch organizations and biotechnology companies. Our tools provideresearchers around the world with the performance, throughput, costeffectiveness and flexibility necessary to perform the billions ofgenetic tests needed to extract valuable medical information fromadvances in genomics and proteomics. We believe this information willenable researchers to correlate genetic variation and biologicalfunction, which will enhance drug discovery and clinical research,allow diseases to be detected earlier and permit better choices ofdrugs for individual patients.
"Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: this release may contain forward-lookingstatements that involve risks and uncertainties. Among the importantfactors that could cause actual results to differ materially fromthose in any forward-looking statements are the costs and outcome ofIllumina's litigation with Affymetrix and our ability (i) to integrateeffectively our recent acquisition of Solexa, Inc., (ii) to developand commercialize further our BeadArray(TM), VeraCode(TM) andSolexa(R) technologies and to deploy new gene expression andgenotyping products and applications for our technology platforms,(iii) to manufacture robust micro arrays and Oligator(R)oligonucleotides, (iv) to integrate and scale our VeraCode technology,(v) to scale further oligo synthesis output and technology to satisfymarket demand derived from our collaboration with Invitrogen, togetherwith other factors detailed in our filings with the Securities andExchange Commission including our recent filings on Forms 10-K and10-Q or in information disclosed in public conference calls, the dateand time of which are released beforehand. We disclaim any intent orobligation to update these forward-looking statements beyond the dateof this release.
Illumina, Inc.
Maurissa Bornstein, Public Relations Manager
858-332-4055
mbornstein@illumina.com
Peter J. Fromen, Sr. Director, IR
858-202-4507
pfromen@illumina.com
or
IntegraGen
Emmanuel Martin, Director, Sales & Marketing
+33 (0) 160 910 907
emmanuel.martin@integragen.com
SOURCE: Illumina, Inc.